β2-Microglobulin in monoclonal gammopathies

Donata Vercelli, F. Cozzolino, A. Becucci, R. Di Guglielmo

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Serum β2m concentrations were evaluated in 130 samples from 77 patients with monoclonal gammopathies (42 multiple myelomas, 35 benign monoclonal gammopathies). A highly significant correlation (P < 0.001) was found between serum β2m and cell mass; mean serum β2m levels were statistically different in the three myeloma stages (P values ranging from P < 0.05 to P < 0.001). When benign monoclonal gammopathies and multiple myelomas were globally compared, mean β2m concentrations were significantly different (P < 0.001), but multiple comparisons showed that no difference existed between benign monoclonal gammopathies and low cell mass (stage I) myelomas. Serum β2m determinations are therefore not clinically useful for the differential diagnosis of monoclonal gammopathies.

Original languageEnglish (US)
Pages (from-to)85-88
Number of pages4
JournalNouvelle Revue Francaise d'Hematologie
Volume24
Issue number2
StatePublished - 1982
Externally publishedYes

Fingerprint

Paraproteinemias
Monoclonal Gammopathy of Undetermined Significance
Serum
Multiple Myeloma
Differential Diagnosis

ASJC Scopus subject areas

  • Hematology

Cite this

Vercelli, D., Cozzolino, F., Becucci, A., & Di Guglielmo, R. (1982). β2-Microglobulin in monoclonal gammopathies. Nouvelle Revue Francaise d'Hematologie, 24(2), 85-88.

β2-Microglobulin in monoclonal gammopathies. / Vercelli, Donata; Cozzolino, F.; Becucci, A.; Di Guglielmo, R.

In: Nouvelle Revue Francaise d'Hematologie, Vol. 24, No. 2, 1982, p. 85-88.

Research output: Contribution to journalArticle

Vercelli, D, Cozzolino, F, Becucci, A & Di Guglielmo, R 1982, 'β2-Microglobulin in monoclonal gammopathies', Nouvelle Revue Francaise d'Hematologie, vol. 24, no. 2, pp. 85-88.
Vercelli D, Cozzolino F, Becucci A, Di Guglielmo R. β2-Microglobulin in monoclonal gammopathies. Nouvelle Revue Francaise d'Hematologie. 1982;24(2):85-88.
Vercelli, Donata ; Cozzolino, F. ; Becucci, A. ; Di Guglielmo, R. / β2-Microglobulin in monoclonal gammopathies. In: Nouvelle Revue Francaise d'Hematologie. 1982 ; Vol. 24, No. 2. pp. 85-88.
@article{f64d286494484c3f9986fe4ef90030ad,
title = "β2-Microglobulin in monoclonal gammopathies",
abstract = "Serum β2m concentrations were evaluated in 130 samples from 77 patients with monoclonal gammopathies (42 multiple myelomas, 35 benign monoclonal gammopathies). A highly significant correlation (P < 0.001) was found between serum β2m and cell mass; mean serum β2m levels were statistically different in the three myeloma stages (P values ranging from P < 0.05 to P < 0.001). When benign monoclonal gammopathies and multiple myelomas were globally compared, mean β2m concentrations were significantly different (P < 0.001), but multiple comparisons showed that no difference existed between benign monoclonal gammopathies and low cell mass (stage I) myelomas. Serum β2m determinations are therefore not clinically useful for the differential diagnosis of monoclonal gammopathies.",
author = "Donata Vercelli and F. Cozzolino and A. Becucci and {Di Guglielmo}, R.",
year = "1982",
language = "English (US)",
volume = "24",
pages = "85--88",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - β2-Microglobulin in monoclonal gammopathies

AU - Vercelli, Donata

AU - Cozzolino, F.

AU - Becucci, A.

AU - Di Guglielmo, R.

PY - 1982

Y1 - 1982

N2 - Serum β2m concentrations were evaluated in 130 samples from 77 patients with monoclonal gammopathies (42 multiple myelomas, 35 benign monoclonal gammopathies). A highly significant correlation (P < 0.001) was found between serum β2m and cell mass; mean serum β2m levels were statistically different in the three myeloma stages (P values ranging from P < 0.05 to P < 0.001). When benign monoclonal gammopathies and multiple myelomas were globally compared, mean β2m concentrations were significantly different (P < 0.001), but multiple comparisons showed that no difference existed between benign monoclonal gammopathies and low cell mass (stage I) myelomas. Serum β2m determinations are therefore not clinically useful for the differential diagnosis of monoclonal gammopathies.

AB - Serum β2m concentrations were evaluated in 130 samples from 77 patients with monoclonal gammopathies (42 multiple myelomas, 35 benign monoclonal gammopathies). A highly significant correlation (P < 0.001) was found between serum β2m and cell mass; mean serum β2m levels were statistically different in the three myeloma stages (P values ranging from P < 0.05 to P < 0.001). When benign monoclonal gammopathies and multiple myelomas were globally compared, mean β2m concentrations were significantly different (P < 0.001), but multiple comparisons showed that no difference existed between benign monoclonal gammopathies and low cell mass (stage I) myelomas. Serum β2m determinations are therefore not clinically useful for the differential diagnosis of monoclonal gammopathies.

UR - http://www.scopus.com/inward/record.url?scp=0020068688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020068688&partnerID=8YFLogxK

M3 - Article

C2 - 6180380

AN - SCOPUS:0020068688

VL - 24

SP - 85

EP - 88

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 2

ER -